Publications by authors named "M M Lumpkin"
Article Synopsis
- Rifaximin is often given to critically ill liver disease patients, but studies typically exclude those recently treated with antibiotics, leading to potential overlap in therapy; a pharmacist-driven protocol was tested to withhold rifaximin during broad-spectrum antibiotic use.
- The study aimed to assess the safety and financial impact of stopping rifaximin in these patients, evaluating outcomes like days free of delirium and coma, ICU length of stay, and cost savings.
- Results showed no significant difference in delirium and coma-free days between patients who had rifaximin withheld and those who received it alongside antibiotics; thus, the protocol did not negatively impact patient safety or outcomes.
Antipsychotic Use for ICU Delirium and Associated Inflammatory Markers.
J Intensive Care Med
April 2024
We sought to evaluate critically ill patients with delirium to evaluate inflammatory cytokine production and delirium progression and the role of antipsychotics. Adult critically ill patients with confirmed delirium according to a positive CAM-ICU score were included and IL-6 and IL-8 levels were trended for 24 h in this single-center, prospective, observational cohort study. A total of 23 patients were consented and had blood samples drawn for inclusion.
View Article and Find Full Text PDFBackground: Essential to the coagulation pathway, vitamin K (phytonadione) is used to correct clotting factor deficiencies and for reversal of warfarin-induced bleeding. In practice, high-dose intravenous (IV) vitamin K is often used, despite limited evidence supporting repeated dosing.
Objective: This study sought to characterize differences in responders and nonresponders to high-dose vitamin K to guide dosing strategies.
USEPA issued drinking water interim health advisories (iHA) for PFOA and PFOS. The Agency's choice for critical effect, toxic point-of-departure (PoD), benchmark dose (BMD), pharmacokinetic (PK) model extrapolation to ingested dose, and use of uncertainty factors, resulted in the iHA for PFOS and PFOA being lowered from 70 ppt to 0.04-0.
View Article and Find Full Text PDF